INS and type 2 diabetes mellitus: Despite this breakthrough and subsequent advances, there is still no causative therapy to prevent or slow down the loss of functional insulin-producing pancreatic β cells, a central hallmark of both type 1 diabetes and type 2 diabetes (T2D).